Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
Eur Respir Rev. 2018 Apr 13;27(148). doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30.
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised medicine a highly attractive concept. Personalised medicine is aimed at describing distinct disease subsets taking into account individual lifestyle, environmental exposures, genetic profiles and molecular pathways. The cornerstone of personalised medicine is the identification of biomarkers that can be used to inform diagnosis, prognosis and treatment stratification. At present, no data exist validating a personalised approach in individual diseases. However, the importance of the goal amply justifies the characterisation of genotype and pathway signatures with a view to refining prognostic evaluation and trial design, with the ultimate aim of selecting treatments according to profiles in individual patients.
一般来说，间质性肺疾病，特别是特发性肺纤维化，是一种具有多种发病途径、多种疾病行为特征和不同治疗反应的复杂疾病，所有这些方面都使得个体化医学成为一个极具吸引力的概念。个体化医学旨在描述不同的疾病亚群，同时考虑到个体的生活方式、环境暴露、基因谱和分子途径。个体化医学的基石是确定生物标志物，这些标志物可用于提供诊断、预后和治疗分层的信息。目前，尚无个体化方法在个别疾病中得到验证的数据。然而，这一目标的重要性充分证明了基因型和途径特征的重要性，这有助于完善预后评估和试验设计，最终目的是根据个体患者的特征选择治疗方法。
